Search company, investor...

CaroGen Corporation


Series A | Alive

Total Raised


Last Raised

$2.08M | 6 yrs ago

About CaroGen Corporation

CaroGen provides a platform technology for generating vaccines, which is based on replication-proficient, virus-like vesicles (rVLVs) allowing target antigens to accumulate in high levels in cells, thereby amplifying specific immune responses and creating more potent immune therapies. The company, which has licensed its core technology from Yale University, will focus initially on a treatment for patients with chronic hepatitis B infections.

Headquarters Location

400 Farmington Ave room 2802

Farmington, Connecticut, 06036,

United States


Missing: CaroGen Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CaroGen Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CaroGen Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CaroGen Corporation is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest CaroGen Corporation News

CaroGen, BioCentriq Enter Clinical Manufacturing Pact

Jun 22, 2021

CaroGen, BioCentriq Enter Clinical Manufacturing Pact CaroGen, BioCentriq Enter Clinical Manufacturing Pact BioCentriq to provide clinical manufacturing to support Phase 1 clinical trials of CaroGen's lead immunotherapy candidate, CARG-201. Pictured from left to right working in CaroGen's UConn incubator lab are Marie Krady, PhD, Senior Research Scientist, Lorraine Apuzzo, PhD Student at UConn and Bijan Almassian, Ph.D. and CEO of CaroGen. 06.22.21 CaroGen Corp. has selected BioCentriq for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201 which has been designed to generate multiple hepatitis B virus (HBV) antigens and to stimulate broad immune responses. BioCentriq is a NJ-based full-service CDMO and offers process development and clinical manufacturing services for the cell and gene therapy industry along with a workforce development arm designed to help the industry adopt best practices in cell and gene therapy manufacturing. CARG-201 is built based on the Artificial Virus for Infectious Diseases and Immuno-Oncology (AVIDIO) platform. AVIDIO of Virus-Like-Vesicles (VLVs) used by CaroGen are an artificial hybrid virus based on an alphavirus RNA replicon and glycoprotein from vesicular stomatitis virus. “CaroGen’s mission is to develop transformative immunotherapies that will recognize and fight infectious diseases of unmet need, like those generated by HBV, that result in chronic liver conditions and cancer” said Bijan Almassian, Ph.D. and CaroGen’s co-founder and CEO. “We are thrilled to have received over $5 million funding from National Institute of Health (NIH) to support our HBV preclinical program and have the opportunity to engage an expert and innovative partner like BioCentriq to help validate our methods, further develop our manufacturing processes and ultimately produce high-quality clinical grade materials.”   “Our team is enthusiastic about the opportunity to help CaroGen scale up their technology and manufacture clinical grade materials that can be made available to the patients who need them the most” said Haro Hartounian, Ph.D., SVP and general manager of BioCentriq. “The work that CaroGen and the team at Yale University has done is truly impressive and we are honored to partner with them as they enter Phase 1 clinical trials.”   06.22.21 06.22.21 06.22.21 06.22.21 06.22.21 06.22.21 06.21.21 06.21.21 06.18.21 06.18.21 06.18.21 06.17.21 06.17.21 06.17.21 06.17.21

CaroGen Corporation Frequently Asked Questions (FAQ)

  • Where is CaroGen Corporation's headquarters?

    CaroGen Corporation's headquarters is located at 400 Farmington Ave, Farmington.

  • What is CaroGen Corporation's latest funding round?

    CaroGen Corporation's latest funding round is Series A.

  • How much did CaroGen Corporation raise?

    CaroGen Corporation raised a total of $2.73M.

  • Who are the investors of CaroGen Corporation?

    Investors of CaroGen Corporation include Connecticut Innovations and Yale University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.